Displaying drugs 10751 - 10775 of 12647 in total
Lecithin
A complex mixture of phospholipids, glycolipids, triglycerides, phosphatidylcholines, phosphatidylethanolamines, and phosphatidylinositols.
Experimental
Matched Description: … A complex mixture of phospholipids, glycolipids, triglycerides, phosphatidylcholines, phosphatidylethanolamines …
DMP-777
DMP-777 is a selective inhibitor of polymorphonuclear leukocyte (PMN) elastase.
Investigational
Matched Description: … DMP-777 is a selective inhibitor of polymorphonuclear leukocyte (PMN) elastase. …
OSSM-007
OSSM-007 consists of interferon-gamma primed allogeneic mesenchymal stem cells.
Investigational
Matched Description: … OSSM-007 consists of interferon-gamma primed allogeneic mesenchymal stem cells. …
APL-030
APL-030 is a orally-active small molecule inhibitor of GCN2.
Investigational
Matched Description: … APL-030 is a orally-active small molecule inhibitor of GCN2. …
Hypoxanthine
Hypoxanthine is a purine and a reaction intermediate in the metabolism of adenosine and in the formation of nucleic acids by the salvage pathway.
Experimental
Matched Description: … of nucleic acids by the salvage pathway. ... Hypoxanthine is a purine and a reaction intermediate in the metabolism of adenosine and in the formation …
Glembatumumab vedotin
A conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer.
Investigational
Matched Description: … for the treatment of melanoma and breast cancer. ... A conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E …
Lexaptepid pegol
Lexaptepid pegol has been used in trials studying the treatment of Anemia, Inflammation, Chronic Diseases, End Stage Renal Disease, and Anemia of Chronic Disease.
Investigational
Matched Description: … , End Stage Renal Disease, and Anemia of Chronic Disease. ... Lexaptepid pegol has been used in trials studying the treatment of Anemia, Inflammation, Chronic Diseases …
25-desacetylrifapentine
25-desacetylrifapentine is under investigation in clinical trial NCT00023387 (TBTC Study 25PK: Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine).
Investigational
Matched Description: … Three Doses of Rifapentine and 25-Desacetyl Rifapentine). ... under investigation in clinical trial NCT00023387 (TBTC Study 25PK: Intensive Pharmacokinetic Study of …
Fluorofuranylnorprogesterone F-18
Fluorofuranylnorprogesterone F-18 is under investigation in clinical trial NCT02455453 (Assessment of Functional Status of Estrogen Receptors in Breast Cancer by Positron Emission Tomography).
Investigational
Matched Description: … Functional Status of Estrogen Receptors in Breast Cancer by Positron Emission Tomography). ... Fluorofuranylnorprogesterone F-18 is under investigation in clinical trial NCT02455453 (Assessment of …
Ridinilazole
Ridinilazole is under investigation in clinical trial NCT02092935 (A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)).
Investigational
Matched Description: … Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)). ... Ridinilazole is under investigation in clinical trial NCT02092935 (A Study of SMT19969 Compared With …
Alunacedase alfa
Alunacedase alfa is a recombinant and soluble glycosylated form of human ACE2. This recombinant version of the enzyme has antihypertensive and potential antineoplastic activities.
Investigational
Matched Description: … Alunacedase alfa is a recombinant and soluble glycosylated form of human ACE2. ... This recombinant version of the enzyme has antihypertensive and potential antineoplastic activities. …
MGN-4893
MGN-4893 is an inhibitor of microRNA-451. In February 2011, it was granted FDA orphan designation for the treatment of polycythemia vera.
Investigational
Matched Description: … MGN-4893 is an inhibitor of microRNA-451. ... In February 2011, it was granted FDA orphan designation for the treatment of polycythemia vera. …
Apelin
Apelin is under investigation in clinical trial NCT03449251 (A Series of Pilot Studies to Evaluate the Haemodynamic and Metabolic Effects of Apelin and Relaxin).
Investigational
Matched Description: … Haemodynamic and Metabolic Effects of Apelin and Relaxin). ... Apelin is under investigation in clinical trial NCT03449251 (A Series of Pilot Studies to Evaluate the …
Aniline
Aniline, phenylamine or aminobenzene is an organic compound with the formula C6H5NH2. Consisting of an amine attached to a benzene ring, aniline is the prototypical aromatic amine. Being a precursor to many industrial chemicals, its main use is in the manufacture of precursors to polyurethane. Like most volatile amines, it...
Experimental
Matched Description: … Like most volatile amines, it possesses the somewhat unpleasant odour of rotten fish. ... Consisting of an amine attached to a benzene ring, aniline is the prototypical aromatic amine. ... Being a precursor to many industrial chemicals, its main use is in the manufacture of precursors to polyurethane …
Cediranib
The novel indole-ether quinazoline Cediranib is a highly potent (IC50 < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro. It is being developed clinically as a once-daily oral therapy for the treatment of cancer.
Investigational
Matched Description: … It is being developed clinically as a once-daily oral therapy for the treatment of cancer. ... quinazoline Cediranib is a highly potent (IC50 < 1 nmol/L) ATP-competitive inhibitor of …
INCB13739
INCB13739 is developed as a new treatment for type 2 diabetes.
It is an orally available small molecule inhibitor of 11beta-HSD1 (11-beta hydroxysteroid dehydrogenase type 1). 11beta-HSD1 is an enzyme that appears to be critical to the development of type 2 diabetes.
Investigational
Matched Description: … It is an orally available small molecule inhibitor of 11beta-HSD1 (11-beta hydroxysteroid dehydrogenase ... type 1). 11beta-HSD1 is an enzyme that appears to be critical to the development of type 2 diabetes. …
rGLP-1
rGLP-1 is a continuous infusion of glucagon-like peptide 1, or GLP-1, targeted for the treatment of congestive heart failure (CHF) in patients ineligible for transplant. GLP-1 is a naturally occurring hormone produced in the intestines in response to food intake.
Investigational
Matched Description: … rGLP-1 is a continuous infusion of glucagon-like peptide 1, or GLP-1, targeted for the treatment of congestive …
RP01
RP01 is a novel anti-IgE immunotherapy for allergic individuals. It is designed to induce the immune system to produce antibodies that block Immunoglobulin E (IgE), the key mediator of an allergic response. It could offer benefit to millions of asthma and allergy patients.
Investigational
Matched Description: … It could offer benefit to millions of asthma and allergy patients. ... induce the immune system to produce antibodies that block Immunoglobulin E (IgE), the key mediator of …
CYT007-TNFQb
CYT007-TNFQb is an active immunization therapy that aims at
providing a novel treatment to people suffering from RA or psoriasis. The vaccine should allow for administration of low
amounts of drug to individual patients (in the microgram range) and for convenient dosing schedules.
Investigational
Matched Description: … The vaccine should allow for administration of low
amounts of drug to individual patients (in the microgram …
alpha-Hydroxy glycineamide
Alpha-hydroxy glycineamide (αHGA) is the active antiviral metabolite of tri-peptide glycyl-prolyl-glycine-amide (GPG-NH2). αHGA inhibits the replication of HIV-1 in vitro by interfering with the capsid formation. It also has an effect on viral gp160 envelope protein.
Investigational
Matched Description: … (GPG-NH2). αHGA inhibits the replication of HIV-1 in vitro by interfering with the capsid formation. ... Alpha-hydroxy glycineamide (αHGA) is the active antiviral metabolite of tri-peptide glycyl-prolyl-glycine-amide …
Ferric oxide
Iron(III) oxide or ferric oxide is the inorganic compound with the formula Fe2O3. It is one of the three main oxides of iron, the other two being iron(II) oxide (FeO) the rarer form, and iron(II,III) oxide (Fe3O4) which naturally as magnetite.
Experimental
Matched Description: … It is one of the three main oxides of iron, the other two being iron(II) oxide (FeO) the rarer form, …
CK0802
CK0802 is an off-the-shelf product composed of allogeneic umbilical cord blood derived regulatory T-cells (T-Reg cells), which can be used intravenously and without HLA matching. On the surface of these T-Reg cells, T-cell lung homing markers are expressed.
Investigational
Matched Description: … [L16358] On the surface of these T-Reg cells, T-cell lung homing markers are expressed. ... CK0802 is an off-the-shelf product composed of allogeneic umbilical cord blood derived regulatory T-cells …
Saposin C
Saposin C is a lysosomal protein. Recombinant, non-glycosylated Saposin C is an active ingredient of BXQ-350, which is a novel, investigational anti-neoplastic therapy. BXQ-350 consists of Saposin C and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes.
Investigational
Matched Description: … BXQ-350 consists of Saposin C and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid ... Recombinant, non-glycosylated Saposin C is an active ingredient of BXQ-350, which is a novel, investigational …
Gemogenovatucel-T
Gemogenovatucel-T is a bi-shRNA furin/Granulocyte Macrophage Colony Stimulating Factor (GMCSF) Augmented autologous tumour cell vaccine. Furin is a convertase involved in the activation of TGFβ-1 and TGFβ-2. Gemogenovatucel-T is being investigated in the treatment of various cancers.
Investigational
Matched Description: … Furin is a convertase involved in the activation of TGFβ-1 and TGFβ-2. ... [A255163] Gemogenovatucel-T is being investigated in the treatment of various cancers. …
VPM4001
VPM4001 is an allogeneic vaccine for treatment of prostate carcinoma. It consists of irradiated human LNCaP cells that have been genetically modified to permanently secrete interferon-γ and interleukin-2 (LNCaP/IL-2/IFN-γ). Interferon-γ enhances presentation of tumour antigens, whereas interleukin-2 stimulates T cells.
Investigational
Matched Description: … VPM4001 is an allogeneic vaccine for treatment of prostate carcinoma. ... Interferon-γ enhances presentation of tumour antigens, whereas interleukin-2 stimulates T cells. ... It consists of irradiated human LNCaP cells that have been genetically modified to permanently secrete …
Displaying drugs 10751 - 10775 of 12647 in total